Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events
In Vivo · 2025
DOI: 10.21873/invivo.13983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift In Vivo, 2025. Verfasst von Hirotaka Suto. Beteiligte Einrichtung: Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan hirotaka.suto@hyogo-cc.jp. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Drug-Related Side Effects and Adverse Reactions, Neoplasms, Immunotherapy. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune-related adverse events (irAEs) are excessive immune responses resembling autoimmune diseases, induced by immune checkpoint inhibitors (ICIs), and can affect organs throughout the body. In contrast to AEs associated with conventional cytotoxic anticancer agents, irAEs may persist or recur after treatment discontinuation. The risk of irAEs recurrence is thought to vary depending on the type and severity of the initial irAE, while the response rate depends on the type and sequence of ICIs re-administered. Therefore, the decision to resume ICI therapy depends on the type and severity of prior irAEs, as well as the anticipated benefits and risks of resumption. This review focuses on the risks and benefits of resuming ICI therapy after each irAE and summarizes the procedure for its resumption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hyogo Cancer Center, Hyogo, Japan hirotaka.suto@hyogo-cc.jp.
Zitieren
APA
Suto, H. (2025). Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events. In Vivo. https://doi.org/10.21873/invivo.13983
Vancouver
Suto H. Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events. In Vivo. 2025. doi:10.21873/invivo.13983
BibTeX
@article{Suto2025,
author = {Suto, Hirotaka},
title = {Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13983}
}
EUVIMED